![](/img/cover-not-exists.png)
41OA phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma
Blum, K A, Abramson, J, Maris, M, Flinn, I, Goy, A, Mertz, J, Sims, R, Garner, F, Senderowicz, A, Younes, AVolume:
29
Language:
english
Journal:
Annals of Oncology
DOI:
10.1093/annonc/mdy048
Date:
March, 2018
File:
PDF, 63 KB
english, 2018